Concord Drugs Ltd
CONCORDConcord Drugs Ltd
CONCORD
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -3,753.00 | 1.11 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Concord Drugs is a pharmaceutical company, engaged in the manufacture of pharmaceutical formulations and the trading of packing material
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2022 | FY 2023 | FY 2024 | TTM | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 59.06 | 52.09 | 44.93 | 47.63 | ||||
Raw Materials | 44.41 | 41.16 | 31.10 | 44.21 | ||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | |||||
| Employee Cost | 4.14 | 3.84 | 5.00 | |||||
| Selling & Administrative Expenses | 1.53 | 2.14 | 2.06 | |||||
| Operating & Other expenses | 3.28 | 0.36 | 2.73 | |||||
EBITDA | 5.70 | 4.59 | 4.04 | 3.42 | ||||
| Depreciation/Amortization | 1.76 | 1.63 | 1.56 | 1.51 | ||||
| PBIT | 3.94 | 2.96 | 2.48 | 1.91 | ||||
| Interest & Other Items | 1.68 | 1.71 | 1.87 | 1.88 | ||||
| PBT | 2.26 | 1.25 | 0.61 | 0.03 | ||||
| Taxes & Other Items | 0.65 | 0.26 | 0.16 | 0.04 | ||||
| Net Income | 1.61 | 0.99 | 0.45 | -0.01 | ||||
| EPS | 1.84 | 1.10 | 0.47 | -0.01 | ||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Concord Drugs Ltd | 83.40 | 1.11 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare CONCORD with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.01%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
CONCORD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeConcord Drugs will hold a meeting of the Board of Directors of the Company on 13 November 2024.Powered by Capital Market - Live
Concord Drugs announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Concord Drugs announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Concord Drugs will hold a meeting of the Board of Directors of the Company on 6 September 2024.Powered by Capital Market - Live
Net profit of Concord Drugs declined 93.88% to Rs 0.03 crore in the quarter ended June 2024 as against Rs 0.49 crore during the previous quarter ended June 2023. Sales rose 30.18% to Rs 11.69 crore in the quarter ended June 2024 as against Rs 8.98 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales11.698.98 30 OPM %7.1016.26 - PBDT0.381.02 -63 PBT0.040.64 -94 NP0.030.49 -94 Powered by Capital Market - Live
Concord Drugs will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live
Concord Drugs standalone net profit rises 7.14% in the December 2022 quarter
Stocks that will see action on September 9, 2022
Concord Drugs standalone net profit rises 475.00% in the September 2021 quarter
Concord Drugs standalone net profit rises 183.33% in the March 2021 quarter
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 1.01%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant